NEW YORK, Dec. 30, 2016 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Avid Technology, Inc. securities (NASDAQ:AVID) from August 4, 2016 through November 9, 2016, inclusive (the “Class Period”) of the important January 20, 2017 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Avid investors under the federal securities laws.
To join the Avid class action, go to http://rosenlegal.com/cases-1003.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
The complaint alleges that during the Class Period, Avid made materially false and misleading statements regarding its business, operations, earnings, and financial prospects. Specifically, the complaint alleges that during the Class Period Avid knew but failed to disclose that because it had not launched all the enterprise level features for its new NEXIS solution product offerings, its enterprise customers were deferring renewals and purchases. The complaint alleges that on November 9, 2016, after the close of trading, Avid suddenly disclosed that both its 3Q16 bookings and revenues had come in considerably lower than the Company had led the investment community to expect, blaming “the transition of the storage product line” and disclosing that “some existing enterprise clients deferred normal upgrade and renewal decisions and new customers postponed investments until the release of functionality targeted to the enterprise market.” The complaint alleges that on this news, Avid’s stock price plummeted 28% on November 10, 2016, on unusually high trading volume.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 20, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1003.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected]. Attorney Advertising. Prior results do not guarantee a similar outcome.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com


CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Unilever and Magnum Face Defamation Lawsuit Over Ben & Jerry's Board Chair Dismissal
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Bank of America's $72.5M Epstein Settlement: What You Need to Know
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Apple Turns 50: From Garage Startup to AI Crossroads 



